# Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress Canonical URL: https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-multiple-presentations-at-the-european-hematology-association-eha-2026-congress Ticker: COGT Company: Cogent Biosciences Source: Cogent Biosciences Published: 2026-05-12 13:30 EST Original Source URL: https://investors.cogentbio.com ## Summary Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings   Preclinical data from selective, potent JAK2 V617F program accepted for poster presentation WALTHAM, Mass. ## Article Body Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings Preclinical data from selective, potent JAK2 V617F program accepted for poster presentation WALTHAM, Mass. ## Recent Company News - 2026-05-30 12:00 EST — [Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-detailed-clinical-data-from-peak-phase-3-trial-with-bezuclastinib-in-combination-with-sunitinib-in-gastrointestinal-stromal-tumors-gist-at-2026-american-society-of-clinical-oncology-asco-annual-meeting) — Source: Cogent Biosciences - 2026-05-28 12:00 EST — [Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-nda-with-priority-review-for-bezuclastinib-in-combination-with-sunitinib-for-patients-with-gist) — Source: Cogent Biosciences - 2026-05-27 12:00 EST — [Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-participation-in-the-2026-jefferies-global-healthcare-conference) — Source: Cogent Biosciences - 2026-05-12 13:30 EST — [Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-multiple-presentations-at-the-european-hematology-association-eha-2026-congress) — Source: Cogent Biosciences - 2026-05-05 12:00 EST — [Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-first-quarter-2026-financial-results) — Source: Cogent Biosciences ## Related News - 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522) - 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043) - 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)